Basal Cell Carcinoma Prognosis and Management

Introduction to Basal Cell Carcinoma

The American Academy of Dermatology notes that basal cell carcinoma is a slow-growing, locally invasive malignancy with an excellent prognosis, with metastasis occurring in less than 0.1% of cases, and mortality is extremely low 1, 2
The primary morbidity stems from local tissue destruction, disfigurement, and functional impairment rather than mortality, as stated by the British Association of Dermatologists 1

BCC typically exhibits slow, indolent growth over months to years, making it fundamentally different from more aggressive skin cancers, according to the National Comprehensive Cancer Network 1
The tumor grows by local invasion rather than distant spread, with progressive enlargement at the primary site, as noted by the British Association of Dermatologists 1, 2
Different histologic subtypes demonstrate varying growth patterns: nodular and superficial types grow more slowly and predictably, while infiltrative, morpheaform, sclerosing, and micronodular subtypes show more aggressive local invasion, as stated by the National Comprehensive Cancer Network 4, 5

The prognosis for BCC is excellent, with cure rates exceeding 95-98% when appropriately treated, according to the National Comprehensive Cancer Network 5, 1
Death from BCC is extraordinarily rare, occurring in less than 0.1% of cases, as noted by the American Academy of Dermatology 3
High-risk features include tumor size ≥2 cm, high-risk anatomic locations, poorly defined clinical margins, aggressive histologic subtypes, perineural or perivascular invasion, recurrent tumors, and immunosuppression, as stated by the British Association of Dermatologists 1, 2, 3
Low-risk features include tumor size <2 cm, location on trunk or extremities, well-defined clinical margins, and non-aggressive histologic subtypes, according to the National Comprehensive Cancer Network 5

Surgical excision with histologic margin assessment achieves 5-year disease-free rates exceeding 98% for appropriately selected BCCs, as noted by the National Comprehensive Cancer Network 5
Curettage and electrodesiccation yields 5-year cure rates of 91-97% for properly selected low-risk tumors, according to the National Comprehensive Cancer Network 5

Basosquamous carcinomas represent a distinct entity with metastatic potential more similar to squamous cell carcinoma than typical BCC, and should be managed as squamous cell carcinomas due to their higher metastatic capacity, as stated by the National Comprehensive Cancer Network 4, 5, 6
Patients who develop one BCC are at significantly increased risk of developing subsequent BCCs at other sites, necessitating long-term surveillance, according to the British Association of Dermatologists 1, 2